A large life sciences manufacturer anticipated that some of its products may be selected for drug price negotiations under the Inflation Reduction Act (IRA). It sought to create an evidence strategy to articulate the value of its products during negotiations and thus needed to predict how CMS might weigh evidence and evaluate results. We helped the client anticipate CMS’s approach to evaluating evidence packages for products during the negotiation process, and develop strategies to strengthen those packages, to ensure that negotiated maximum fair prices (MFPs) accurately reflect the value of the client’s products.
Featured Insight
Trusted Partnership
We partner closely with clients to ensure their IRA strategy is tailored to their industry position, needs, and goals, helping clients make informed decisions and achieve long-term success.
Insight
Planning for Life Sciences
Medicare drug price negotiation will have long-lasting ripple effects across therapeutic markets, and manufacturers will need to adopt a product-specific approach to stay ahead of the changing drug landscape. Avalere experts in policy, CMS engagement, market access, and evidence assessment help manufacturers reassess their strategies to stay ahead of the changing drug landscape.
Engage an Avalere Expert Today
Featured Expertise
Related Content
Federal and State Policy
Opportunities to Prepare for Year 2 of Medicare Negotiation
Federal and State Policy
IRA Question of the Week: How May the IRA Shift Part D Market Dynamics?
Key Considerations for MFP Effectuation and the 340B Rebate Model
Stakeholders consider implementation of a 340B rebate model to address duplicate discount risk.
Manufacturer Learnings from the First Round of Negotiated MFPs
Avalere experts share initial impressions of the publicly released negotiated MFPs for the first round of selected drugs, highlighting implications to industry.
Potential Impacts of IPAY 2026 Maximum Fair Prices on Health Plan Formulary Negotiations
With the release of the IPAY 2026 MFPs, health plans should analyze the impact to formularies and identify opportunities for contracting changes.
Health Policy in the 2024 Election: Avalere and Outside Experts Weigh In
With the election fast approaching, former HHS Secretary Alex Azar, Dan Mendelson, and Avalere experts discussed implications for healthcare stakeholders.
Updated Negotiation ICR Presents New Industry Evidence Needs
Updates in the Initial IPAY 2027 ICR highlight the increasing needs for specific evidence planning and generation for industry to prepare for negotiation.
Opportunities to Prepare for Year 2 of Medicare Negotiation
Manufacturers anticipating potential selection or therapeutic impact for 2027 Medicare negotiations should begin preparations and align internal decision-making, applying learnings from Year 1.
Part D Risk Adjustment Will Have New Importance Under IRA
Analysis of data in the CMS VRDC shows that MA-PD utilization has steadily increased in therapeutic areas likely to have large increases in plan liability under Part D redesign.
IRA Reforms Will Impact Patient Adherence and Affordability
With increased patient utilization and plan formulary responses to Part D redesign, many patients may still face affordability challenges under the IRA.
IRA Negotiation Creates Ripple Effects Across Drug Markets
Medicare negotiation has ripple effects across therapeutic markets, requiring manufacturers to reassess strategies to stay ahead of the changing drug landscape.
IRA Drug Price Negotiation Impact on Cardiovascular Drugs
A new Avalere white paper raises important considerations on potential added lifecycle pressures for sponsors of cardiovascular disease products.
Please wait ...